Skip to main content
SpringerLink
Log in

Seeing with new eyes: Finding a path to early intervention trials in Alzheimer’s disease

  • Published:
The journal of nutrition, health & aging

Abstract

The clinical course of Alzheimer’s Disease (AD) and other degenerative disorders affecting cognition can be visualized as a progression from normal cognition through the syndrome of Mild Cognitive Impairment (MCI) to dementia. The use of biomarker data can supplement clinical characterization and identification of MCI and dementia pathologies. Clinical staging algorithms that use both clinical and biomarker information can assist in the early identification of AD patients. A comprehensive outcome measure such as the Clinical Dementia Rating Sum of Boxes (CDR-SB), which has components that assess both cognitive and functional domains in parallel deserves consideration as a primary outcome measure for early AD clinical trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV et al. Current Concepts I Mild Cognitive Impairment. Arch Neurol 2001;58:1985–1992.

    Article  CAS  PubMed  Google Scholar 

  2. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984;34:939–944.

    CAS  PubMed  Google Scholar 

  3. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999;56:303–308.

    Article  CAS  PubMed  Google Scholar 

  4. Petersen RC, Morris JC. Mild Cognitive Impairment as a Clinical Entity and Treatment Target. Arch. Neurol 2005;62:1160–1163.

    Article  PubMed  Google Scholar 

  5. Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 2007;69:2197–2204.

    Article  PubMed  Google Scholar 

  6. Petersen, RC. Early Diagnosis of Alzheimer’s disease: Is MCI too late? Current Alzhimer’s Research 2009;6:324–330.

    Article  CAS  Google Scholar 

  7. Sunderland T, Wolozin B, Galasko D, Levy J, Dukoff R, Bahro M, et al. Longitudinal stability of CSF tau levels in Alzheimer subjects. Biol Psychiatry. 1999 15;46:750–755.

    Article  CAS  PubMed  Google Scholar 

  8. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer’s disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006;5:228–234.

    Article  CAS  PubMed  Google Scholar 

  9. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann Neurol 2004;55:306–319.

    Article  CAS  PubMed  Google Scholar 

  10. Mintun MA, Larossa GN, Sheline YI, Dence CS, Lee SY, Mach RH, et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 2006;67:446–452.

    Article  CAS  PubMed  Google Scholar 

  11. McKeith I, O’Brien J, Walker Z, Tatsch K, Booij, Darcourt J. Sensitivity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol 2007;6:305–313.

    Article  PubMed  Google Scholar 

  12. Sleegers K, Brouwers N, Van Damme P, Engelborghs S, Gijselinck I, van der Zee J, et al. Serum biomarker for progranulin-associated frontotemporal lobar degeneration. Ann Neurol. 2009;65:603–609.

    Article  CAS  PubMed  Google Scholar 

  13. Mollenhauer B, Cullen V, Kahn I, Krastins B, Outeiro TF, Pepivani I, et al. Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp Neurol. 2008;213:315–325.

    Article  CAS  PubMed  Google Scholar 

  14. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, et al. Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007:734–746.

  15. Dubois B. ’Prodromal Alzheimer’s disease’: a more useful concept than mild cognitive impairment? Curr Opin Neurol. 2000;13:367–369.

    Article  CAS  PubMed  Google Scholar 

  16. Frisoni GB, Padovani A, Wahlund LO. The predementia diagnosis of Alzheimer disease. Alzheimer Dis Assoc Disord. 2004;18:51–53.

    Article  PubMed  Google Scholar 

  17. Morris JC, McKeel DW, Sorandt M, Rubin EH, Price JL, Grant MJ et al. Very mild Alzheimer’s disease: Informant-based clinical, psychometric and pathologic distinction from normal aging. Neurology 1991;41:463–448.

    Google Scholar 

  18. Bennett DA. Existing Evidence for Presymptomatic and Preclinical AD: What is AD and when does it begin? Presented at the Alzheimer’s Association Research Roundtable, “Early Risk Assessment for Alzheimer’s Disease”. Washington, DC. November 13, 2007.

  19. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, et al. Alzheimer’s Disease Neuroimaging Initiative. Cerebrospinal fluid biomarker signature in Alzheimer’s disease neuroimaging initiative subjects. Ann Neurol. 2009;65:403–113.

    Article  CAS  PubMed  Google Scholar 

  20. Jack CR, Lowe VJ, Weigand SD, Wiste HJ, Senjem ML, Knopman DS, et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer’s disease: implications for sequence of pathological events in Alzheimer’s disease. Brain 2009;132:1355–1365.

    Article  PubMed  Google Scholar 

  21. Vemuri P, Wiste HJ, Weigand SD, Shaw LM, Trojanowski JQ, Weiner MW, et al. MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change. Neurology. 2009;73:294–301.

    Article  CAS  PubMed  Google Scholar 

  22. Committee for Medicinal Products for Human Use (CHMP). Guideline on medicinal products for the treatment of Alzheimer’s disease and other dementias. European Medicines Agency Pre-Authorisation Evaluation of Medicines for Human Use. London, 24 July 2008. Doc. Ref. CPMP/EWP/553/95 Rev.1.

  23. Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, et al. Clinical effects of AD immunization (AN1792) in subjects with AD in an interrupted trial. Neurology 2005;64:1553–1562.

    Article  CAS  PubMed  Google Scholar 

  24. Harrison J, Minassian SM, Jenkins L, Black RS, Koller M, Grundman M. The NTB: A neuropsychological test Battery for Use in Alzheimer’s Disease Clinical Trials. Arch Neurol 2007 64:1323–1329.

    Article  PubMed  Google Scholar 

  25. Grundman M, Black R, Liu E, Motali R, Zawadzki R, McLaughlin T. The Neuropsychological Test Battery discriminates patients with Mild Cognitive Impairment from normal controls and Alzheimer’s disease. Alzheimer’s & Dementia 2008;4:T560.

    Article  Google Scholar 

  26. Fahn S, Elton RI, UPDRS Program Members. Unified Parkinson’s disease rating scale. In: Fhn, S. Marsden CD, Goldstein M, Calne DB (eds). Recent developments in Parkinsons’ Disease, Vol. 2. Florham Park NJ: Macmillan Healthcare Information 1987. 153–163.

    Google Scholar 

  27. Olanow CW, Hauser RA, Jankovic J, Langston W, Lang A, Poewe W, et al. A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson’s disease (the ADAGIO stud.

  28. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993;43:2412–2414.

    CAS  PubMed  Google Scholar 

  29. O’Bryant SE, Waring SC, Cullum M, Hall J, Lactriz L, Massman PJ, et al. Staging dementia using Clinical Dementia Rating Scale Sum of Boxes Scores. Arch Neurol 2008;65:1091–1095.

    Article  PubMed  Google Scholar 

  30. Aisen, P. ADNI and Early AD Trials. Presented at the American Academy of Neurology, April 2009.

  31. Tractenberg RE, Weiner MF, Cummings JL, Patterson MB, Thal LJ. Independence of changes in behavior from cognition and function in community-dwelling persons with Alzheimer’s disease: a factor analytic approach. J Neuropsychiatry Clin Neurosci. 2005;17:51–60.

    PubMed  Google Scholar 

  32. Morris JC, Ernesto C, Schafer K, Coats M, Leon S, Sano M et al. Clinical Dementia Rating Training and reliability in multicenter studies: The Alzheimer’s Disease Cooperative Study Experience Neurology 1997;47:1508–1510.

    Google Scholar 

  33. Rockwood K, Strang D, MacKnight C, Downer R, Morris JC. Interrater reliability of the Clinical Dementia Rating in a multicenter Trial. J Am Geriatr Soc 2000;48:558–559.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Elan Pharmaceuticals, Inc., 800 Gateway Boulevard, South San Francisco, CA, 94080, USA

    J. M. Cedarbaum, G. Crans & M. Grundman

Authors
  1. J. M. Cedarbaum
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. Crans
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Grundman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. M. Cedarbaum.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cedarbaum, J.M., Crans, G. & Grundman, M. Seeing with new eyes: Finding a path to early intervention trials in Alzheimer’s disease. J Nutr Health Aging 14, 306–309 (2010). https://doi.org/10.1007/s12603-010-0069-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12603-010-0069-y

Key words

Search

Navigation